Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study

doi:10.3969/j.issn.1006-7795.2022.02.021

Abstract

Abstract: Objective To assess the efficacy and safety of icotinib plus antiangiogenic agent for epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC). Methods From June 1, 2018 to December 31, 2019, in the Department of Thoracic Surgery of Xuanwu Hospital, Capital Medical University, we summarized the experience with icotinib plus antiangiogenic agent as the first-line treatment in 37 patients with advanced EGFR mutant lung adenocarcinoma. The patients received icotinib (125 mg, three times per day) combined with bevacizumab (7.5 mg/kg, every three weeks) or icotinib (125 mg, three times per day) combined with anlotinib (10-12 mg, daily, day 1-14) until disease progression or unacceptable toxicity. Each regimen was 21-day per cycle. The median follow-up was 14.5(9.2-30.8)months. Results In this study, 62.2％(23/37) achieved partial remissions and 37.8％ (14/37) achieved stable diseases. The objective response rate was 62.2％(23/37) and disease control rate was 100%. The median progression-free survival was 17.9(95%CI:10.292-25.508)months.One-year overall survival (OS) rate was 83.8％ and 18-month OS 81.1％.According to multivariate analysis, patients with liver metastasis or brain metastasis had significantly worse prognosis (P<0.05). Rash (43.2%, 16/37)and diarrhea(21.6%, 8/37) were predominant adverse events. Conclusion The combination of icotinib and antiangiogenic agent appears to be an efficient and well-tolerated regimen as first-line treatment for advanced EGFR mutant lung adenocarcinoma patients.

Key words: lung adenocarcinoma, epidermal growth factor receptor mutation, targeted therapy, antiangiogenic agent

CLC Number:

R587.1

Yao Shuyang, Li Xiaoxue, Wang Chunxiu, Zhang Yi. Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study[J]. Journal of Capital Medical University, 2022, 43(2): 289-293.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.02.021

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I2/289

References

[1] Herbst R S, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[2] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
[3] Wu Y L, Zhou C C, Hu C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2): 213-222.
[4] Ichihara E, Hotta K, Nogami N, et al. Phase Ⅱ trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001[J]. J Thorac Oncol, 2015, 10(3): 486-491.
[5] Ichihara E, Ohashi K, Takigawa N, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo[J]. Cancer Res, 2009, 69(12): 5091-5098.
[6] Ninomiya T, Nogami N, Kozuki T, et al. A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404[J]. Lung Cancer, 2018, 115: 103-108.
[7] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[8] Ettinger D S, Wood D E, Aisner D L, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[9] 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. Ⅳ期原发性肺癌中国治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(1): 39-59.
[10] Shi Y K, Zhang L, Liu X Q, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961.
[11] Shi Y K, Wang L, Han B H, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 28(10): 2443-2450.
[12] Xu L S, Qi Q, Zhang Y, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31.
[13] Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625-635.
[14] Nakagawa K, Garon E B, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(12): 1655-1669.
[15] Qu J, Wang Y N, Xu P, et al. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a Meta-analysis[J]. Oncotarget, 2017, 8(20): 33961-33971.